GLUCOSE 5 % INTRAVENOUS INFUSION BP Israel - English - Ministry of Health

glucose 5 % intravenous infusion bp

teva medical marketing ltd. - glucose monohydrate - solution for infusion - glucose monohydrate 5.5 %w/v - glucose - glucose - glucose 5 % intravenous infusion is indicated for the treatment of carbohydrate and fluid depletion. glucose 5 % is also used as a vehicle and diluent for compatible medicinal products for parenteral administration.

BAXTER 25% GLUCOSE 250mg/L injection AHB0224 Australia - English - Department of Health (Therapeutic Goods Administration)

baxter 25% glucose 250mg/l injection ahb0224

baxter healthcare pty ltd - glucose, quantity: 250 g/l - injection, solution - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

GLUCOSE 5 % INTRAVENOUS INFUSION BP Israel - English - Ministry of Health

glucose 5 % intravenous infusion bp

teva medical marketing ltd. - glucose monohydrate - solution for infusion - glucose monohydrate 5.5 %w/v - glucose - glucose - for the treatment of carbohydrate and fluid depletion. glucose 5 % is also used as a vehicle and diluent for compatible medicinal products for parenteral administration.

Glucose 5% Intravenous Infusion BP Malta - English - Medicines Authority

glucose 5% intravenous infusion bp

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - glucose monohydrate - solution for infusion - glucose monohydrate 50 g/l - blood substitutes and perfusion solutions

BAXTER 0.9% SODIUM CHLORIDE and 5% GLUCOSE 1000mL injection AHB1064 Australia - English - Department of Health (Therapeutic Goods Administration)

baxter 0.9% sodium chloride and 5% glucose 1000ml injection ahb1064

baxter healthcare pty ltd - glucose, quantity: 50 g/l; sodium chloride, quantity: 9 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - sodium chloride (%) and glucose (%) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium and chloride ion concentrations. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Baxter 20 mmol Potassium Chloride, 5% Glucose and 0.45% Sodium Chloride injection for intravenous infusion 1000 mL bag (AHB6024) Australia - English - Department of Health (Therapeutic Goods Administration)

baxter 20 mmol potassium chloride, 5% glucose and 0.45% sodium chloride injection for intravenous infusion 1000 ml bag (ahb6024)

baxter healthcare pty ltd - potassium chloride, quantity: 1.49 g/l; glucose, quantity: 50 g/l; sodium chloride, quantity: 4.5 g/l - injection - excipient ingredients: water for injections - the potassium chloride, sodium chloride and glucose intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Baxter 20 mmol Potassium Chloride, 5% Glucose and 0.9% Sodium Chloride injection for intravenous infusion 1000 mL bag (AHB6066) Australia - English - Department of Health (Therapeutic Goods Administration)

baxter 20 mmol potassium chloride, 5% glucose and 0.9% sodium chloride injection for intravenous infusion 1000 ml bag (ahb6066)

baxter healthcare pty ltd - potassium chloride, quantity: 1.49 g/l; glucose, quantity: 50 g/l; sodium chloride, quantity: 9 g/l - injection - excipient ingredients: water for injections - the potassium chloride, sodium chloride and glucose intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Glucose 5% Intravenous Infusion BP Malta - English - Medicines Authority

glucose 5% intravenous infusion bp

baxter healthcare limited - glucose monohydrate - solution for infusion - glucose monohydrate 50 g/l - blood substitutes and perfusion solutions

BAXTER Compound Sodium Lactate Solution and 5% Glucose 1000mL injection AHB2074 Australia - English - Department of Health (Therapeutic Goods Administration)

baxter compound sodium lactate solution and 5% glucose 1000ml injection ahb2074

baxter healthcare pty ltd - glucose, quantity: 50 g/l; sodium chloride, quantity: 6 g/l; sodium lactate, quantity: 3.22 g/l; potassium chloride, quantity: 400 mg/l; calcium chloride dihydrate, quantity: 270 mg/l - injection, solution - excipient ingredients: water for injections - compound sodium lactate solution and 5% glucose is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are compatible with the solutions.

BAXTER Compound Sodium Lactate Solution and 5% Glucose 500mL injection AHB2073 Australia - English - Department of Health (Therapeutic Goods Administration)

baxter compound sodium lactate solution and 5% glucose 500ml injection ahb2073

baxter healthcare pty ltd - glucose, quantity: 50 g/l; sodium chloride, quantity: 6 g/l; sodium lactate, quantity: 3.22 g/l; potassium chloride, quantity: 400 mg/l; calcium chloride dihydrate, quantity: 270 mg/l - injection, solution - excipient ingredients: water for injections - compound sodium lactate solution and 5% glucose is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are compatible with the solutions.